Abstract: Objective To evaluate the therapeutic effects of different therapeutic regimens for non-small-cell lung cancer
(NSCLC) with or without EML4-ALK rearrangement. Methods Twenty-one ALK-positive and 50 ALK-negative NSCLC
patients who received voluntarily EML4-ALK testing and 75 NSCLC patients without AL testing were enrolled in this study.
The 3 groups of patients received different treatments, and the therapeutic effects, progression-free survival (PFS), and
treatment-related adverse events were analyzed. Result Crizotinib treatment obviously prolonged the PFS in
EML4-ALK-positive patients with an objective response rate (OOR) of 61.9% and a median response duration of 16 months,
which were significantly better than those in with ALK-negative patients and patients without ALK testing who received
different second-line therapies. Conclusion Crizotinib is superior to platinum-based chemotherapy in NSCLC patients with
ALK rearrangement. ALK rearrangement id not a modifier of the effect of chemotherapy regimens in NSCLC patients.